Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000934
Chunk: 47

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 47
---
 such business combination would own less than a 50.0% of the outstanding shares of the Company immediately following the effective
time of such business combination.

| -24- |

(k) .
From and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its commercially
reasonable efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security
or solicit any offers to buy any security, under circumstances that would reasonably be expected to (i) require registration of the offer
and sale by the Company to the Investor of any of the Securities under the Securities Act, or (ii) cause this offering of the Securities
by the Company to the Investor to be integrated with other offerings by the Company in a manner that would require shareholder approval
pursuant to the rules of the Principal Market, unless in the case of this clause and (iii), shareholder approval is obtained before the
closing of such subsequent transaction in accordance with the rules of such Principal Market, if applicable.

(l) . Except as expressly set forth in the Transaction Documents or any other writing to the contrary, each party shall pay
the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation and preparation this Agreement, that on the Execution Date, the Company shall pay a document
preparation fee to the Investor to reimburse up to $35,000 of the Investor’s legal fees.

(m) . The Investor shall have the right to request and receive up to once per fiscal quarter, upon five (5) days prior
written notice, a certificate, executed by the CEO, President or CFO of the Company in the form attached hereto as , certifying
that the representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any
of such representations and warranties is already qualified as to materiality in Section 4 above, in which case, the portion of such representations
and warranties so qualified shall be true and correct without further qualification) as of such date and as though made at that time (except
for representations and warranties that speak as of a specific date, which shall be true and correct as of such date) and the Company
shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by the Transaction
Documents to be performed, satisfied or complied